Per Lund
Overview
Explore the profile of Per Lund including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lund P, Kotova I, Kedinger V, Khanwalkar H, Voltz E, Hahn W, et al.
Mol Cancer Ther
. 2011 Jun;
10(9):1611-23.
PMID: 21697397
TNF-related apoptosis-inducing ligand (TRAIL) kills tumor cells selectively. We asked how emerging tumor cells escape elimination by TRAIL and how tumor-specific killing by TRAIL could then be restored. We found...
2.
Jurchott K, Kuban R, Krech T, Bluthgen N, Stein U, Walther W, et al.
PLoS Genet
. 2010 Dec;
6(12):e1001231.
PMID: 21170361
Transcriptional signatures are an indispensible source of correlative information on disease-related molecular alterations on a genome-wide level. Numerous candidate genes involved in disease and in factors of predictive, as well...
3.
Sers C, Kuner R, Falk C, Lund P, Sueltmann H, Braun M, et al.
Int J Cancer
. 2009 Jul;
125(7):1626-39.
PMID: 19569244
Most malignant features of cancer cells are triggered by activated oncogenes and the loss of tumor suppressors due to mutation or epigenetic inactivation. It is still unclear, to what extend...
4.
Breum L, Almdal T, Eiken P, Lund P, Christiansen E
Rev Diabet Stud
. 2008 Dec;
5(3):154-62.
PMID: 19099087
Objective: To investigate tolerability and glycemic control over 26 weeks in patients with type 2 diabetes (T2D) who initiated insulin with, or switched to, biphasic insulin aspart 30/70 (BIAsp 30)...
5.
Hermansen K, Lund P, Clemmensen K, Breum L, Moller M, Rosenfalck A, et al.
Rev Diabet Stud
. 2007 Sep;
4(2):89-97.
PMID: 17823693
PREDICTIVEtrade mark is a large, multi-national, open-label, prospective, observational study to assess the efficacy and safety of insulin detemir in clinical practice. We report 3-month follow-up data from 389 patients...
6.
Schafer R, Tchernitsa O, Gyorffy B, Serra V, Abdul-Ghani R, Lund P, et al.
Adv Enzyme Regul
. 2007 Mar;
47:41-62.
PMID: 17335873
No abstract available.
7.
Refsum N, Fredriksen G, Lund P, Naalsund L, Sandal J, Thorsen A
Tidsskr Nor Laegeforen
. 2004 May;
124(9):1263-4.
PMID: 15131712
No abstract available.
8.
Tchernitsa O, Sers C, Zuber J, Hinzmann B, Grips M, Schramme A, et al.
Oncogene
. 2004 Apr;
23(26):4536-55.
PMID: 15064704
To understand the relationship between oncogenic signaling and the reprogramming of gene expression, we performed transcriptional profiling in rat ovarian surface epithelial cells (ROSE), in which neoplastic transformation is driven...
9.
Lund P, Schubert D, Niketeghad F, Schirmacher P
Cancer Lett
. 2004 Mar;
206(1):85-96.
PMID: 15019164
Insulin-like Growth Factor (IGF)-II is frequently overexpressed in experimental and human hepatocellular carcinomas (HCCs) and has been correlated with increased tumor growth. We have analyzed, whether IGF-II affects chemotherapy response...